Cara Cassino
Net worth: - $ as of 2024-03-30
Profile
Cara Cassino worked as an Executive Medical Director at Boehringer Ingelheim Pharmaceuticals, Inc. from 2001 to 2007.
She then worked as the Group VP-Pulmonary Vascular & Rare Diseases at Pfizer Inc. from 2008 to 2013.
In 2014, she was the Senior Vice President at Forest Laboratories, Inc. From 2015 to 2022, she worked as the Chief Medical Officer & EVP-Research & Development at ContraFect Corp.
Prior to her business career, she was a Member of the Pulmonary & Critical Care Medicine Division at New York University School of Medicine.
She earned her doctorate from New York University School of Medicine and her undergraduate degree from NYU College of Dentistry.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CONTRAFECT CORP.
-.--% | 2023-09-05 | 0 ( -.--% ) | - $ | 2024-03-30 |
Former positions of Cara Cassino
| Companies | Position | End |
|---|---|---|
| CONTRAFECT CORPORATION | Chief Tech/Sci/R&D Officer | 2022-08-13 |
| FOREST LABORATORIES, INC. | Corporate Officer/Principal | 2015-08-31 |
| PFIZER, INC. | Corporate Officer/Principal | 2012-12-31 |
Boehringer Ingelheim Pharmaceuticals, Inc.
 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Chief Tech/Sci/R&D Officer | 2006-12-31 |
| New York University School of Medicine | Corporate Officer/Principal | - |
Training of Cara Cassino
| NYU College of Dentistry | Undergraduate Degree |
| New York University School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| CONTRAFECT CORPORATION | Health Technology |
| Private companies | 2 |
|---|---|
Forest Laboratories, Inc.
 Forest Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Forest Laboratories, Inc. is engaged in the development, manufacture, and sale of branded forms of drug products. Its products include Bystolic, which is used to decrease heart rate and myocardial contractility; Daliresp, which is used to reduce the risk of chronic obstructive pulmonary disease exacerbation; Linzess, which is used in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; and Namenda, which is used in the treatment of moderate to severe dementia. The company was founded in 1954 and is headquartered in New York, NY. | Health Technology |
Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Health Technology |
- Stock Market
- Insiders
- Cara Cassino
